Abu Saleh Md Moin
Platelet Protein-Related Abnormalities in Response to Acute Hypoglycemia in Type 2 Diabetes
Moin, Abu Saleh Md; Al-Qaissi, Ahmed; Sathyapalan, Thozhukat; Atkin, Stephen L.; Butler, Alexandra E.
Stephen L. Atkin
Alexandra E. Butler
Introduction: Patients with severe COVID-19 infections have coagulation abnormalities indicative of a hypercoagulable state, with thromboembolic complications and increased mortality. Platelets are recognized as mediators of inflammation, releasing proinflammatory and prothrombotic factors, and are hyperactivated in COVID-19 infected patients. Activated platelets have also been reported in type 2 diabetes (T2D) patients, putting these patients at higher risk for thromboembolic complications of COVID-19 infection.
Methods: A case-control study of T2D (n=33) and control subjects (n=30) who underwent a hyperinsulinemic clamp to induce normoglycemia in T2D subjects: T2D: baseline glucose 7.5 ± 0.3mmol/l (135.1 ± 5.4mg/dl), reduced to 4.5 ± 0.07mmol/l (81 ± 1.2mg/dl) with 1-hour clamp; Controls: maintained at 5.1 ± 0.1mmol/l (91.9 ± 1.8mg/dl). Slow Off-rate Modified Aptamer (SOMA)-scan plasma protein measurement was used to determine a panel of platelet proteins.
Results: Prothrombotic platelet proteins were elevated in T2D versus controls: platelet factor 4 (PF4, p < 0.05); platelet glycoprotein VI (PGVI p < 0.05); P-selectin (p < 0.01) and plasminogen activator inhibitor I (PAI-1, p < 0.01). In addition, the antithrombotic platelet-related proteins, plasmin (p < 0.05) and heparin cofactor II (HCFII, p < 0.05), were increased in T2D. Normalization of glucose in the T2D cohort had no effect on platelet protein levels.
Conclusion: T2D patients have platelet hyperactivation, placing them at higher risk for thromboembolic events. When infected with COVID-19, this risk may be compounded, and their propensity for a more severe COVID-19 disease course increased.
Moin, A. S. M., Al-Qaissi, A., Sathyapalan, T., Atkin, S. L., & Butler, A. E. (2021). Platelet Protein-Related Abnormalities in Response to Acute Hypoglycemia in Type 2 Diabetes. Frontiers in endocrinology, 12, https://doi.org/10.3389/fendo.2021.651009
|Journal Article Type||Article|
|Acceptance Date||Mar 16, 2021|
|Online Publication Date||Mar 30, 2021|
|Publication Date||Mar 30, 2021|
|Deposit Date||May 15, 2021|
|Publicly Available Date||May 18, 2021|
|Journal||Frontiers in Endocrinology|
|Peer Reviewed||Peer Reviewed|
|Keywords||Type 2 diabetes; Obesity; Platelet; COVID-19, SARS-CoV-2|
Publisher Licence URL
Copyright © 2021 Moin, Al-Qaissi, Sathyapalan, Atkin and Butler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
You might also like
Renin-angiotensin system overactivation in type 2 diabetes: A risk for SARS-CoV-2 infection?
Anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome
Plasma heat shock protein response to euglycemia in type 2 diabetes